HPV Infections Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women
Verified date | January 2019 |
Source | Merck Sharp & Dohme Corp. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among Chinese females between the ages of 20 and 45.
Status | Completed |
Enrollment | 3006 |
Est. completion date | September 30, 2016 |
Est. primary completion date | May 11, 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 20 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Healthy women between the ages of 20 and 45 - Have used effective contraception for 2 weeks prior to starting in the study - Does not have a temperature within 24 hours before the first injection Exclusion Criteria: - Prior history of genital warts - More than 4 lifetime sexual partners - Have undergone hysterectomy - Have active cervical disease or history of cervical disease |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme Corp. |
Wei L, Xie X, Liu J, Zhao Y, Chen W, Zhao C, Wang S, Liao X, Shou Q, Qiu Y, Qiao Y, Saah AJ. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. Vaccine. 2018 Aug 16. pii: S0264-410X(18)31116-2. doi: 10.1016/j.vaccine.2018.08.009. [Epub ahead of print] — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (Test of Hypothesis) | The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by polymerase chain reaction (PCR) in an adjacent section from the same tissue block. | From Day 1 until >=25 cases accumulate, up to Month 30 | |
Primary | Base Study: Combined Incidence of 6-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Years Old Participants (Test of Hypothesis) | The endpoint included pathology panel consensus diagnosis of 6-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block. | From Day 1 until >=17 cases accumulate, up to Month 30 | |
Primary | Entire Study: Combined Incidence of CIN2+ Related to HPV Types 16 or 18 in 20 to 45 Year Old Participants (End of Study Test of Hypothesis) | The endpoint included pathology panel consensus diagnosis of CIN2+ (including CIN grade 2 or 3, AIS, and cervical cancer) related to HPV Types 16 or 18 detected by PCR in an adjacent section from the same tissue block. | Up to Month 78 | |
Primary | Base Study: Percentage of Participants With One or More Solicited Injection-site Adverse Events | An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. Injection-site AEs were prompted on the Vaccination Report Card (VRC), which was completed by the participant for 15 days after each vaccination. | Up to 15 days after any vaccination | |
Primary | Base Study: Percentage of Participants With One or More Systemic Adverse Events | An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. | Up to 15 days after any vaccination | |
Primary | Base Study: Percentage of Participants Discontinued From Study Vaccination Due to an Adverse Event | An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. | Up to 6 months | |
Primary | Entire Study: Percentage of Participants With One or More Vaccine-related Serious Adverse Events | A serious adverse event (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is an overdose or, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention. Related SAEs were those deemed possibly, probably, or definitely related to study vaccine or a study procedure. | Up to approximately 90 months | |
Primary | Entire Study: Percentage of Participants Who Died | The percentage of participants who died on study due to any cause, whether or not related to the investigational product, were reported for each arm | Up to approximately 90 months | |
Secondary | Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 45 Year Old Participants (End of Study Update) | The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block. | Up to 78 months | |
Secondary | Entire Study: Combined Incidence of 12-Month Persistent Infection, CIN+, and External Genital Lesions Related to Human Papillomavirus (HPV) Type 6, 11, 16, or 18 in 20 to 26 Year Old Participants (End of Study Update) | The endpoint included pathology panel consensus diagnosis of 12-month persistent infection, CIN+ (including CIN grade 1, 2, or 3, cervical adenocarcinoma in situ (AIS), and cervical cancer), or external genital lesions related to HPV Types 6, 11, 16, or 18 detected by PCR in an adjacent section from the same tissue block. | Up to 78 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00956553 -
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
|
Phase 4 | |
Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
Suspended |
NCT00733122 -
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
|
Phase 3 | |
Recruiting |
NCT04895020 -
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
|
Phase 3 | |
Recruiting |
NCT05371353 -
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
|
||
Completed |
NCT03900572 -
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
|
Phase 1 | |
Completed |
NCT00635830 -
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
|
Phase 1 | |
Not yet recruiting |
NCT01021904 -
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
|
Phase 4 | |
Completed |
NCT00378560 -
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
|
Phase 2 | |
Completed |
NCT00682812 -
Significance of the High-risk Hpv Viral Load
|
N/A | |
Completed |
NCT01086709 -
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
|
||
Completed |
NCT00711815 -
A Study to Identify Markers in Blood and Tissue of HPV Clearance
|
N/A | |
Completed |
NCT03085381 -
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
|
Phase 1 | |
Completed |
NCT00847340 -
Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population
|
N/A | |
Completed |
NCT00411749 -
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
|
Phase 2 | |
Completed |
NCT00943722 -
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
|
Phase 3 |